AFMS Collaborates With IIT Delhi To Develop Medical Devices

New Delhi: Armed Forces Medical Services and IIT-Delhi on Monday joined hands to undertake collaborative research to develop novel medical devices and focus on solving health issues specific to serving soldiers in varied terrains.

AFMS signed a Memorandum of Understanding (MoU) for collaborative research and training with the Indian Institute of Technology-Delhi.

“The scope of this MoU includes undertaking research and innovation to develop novel medical devices and focus on solving health issues specific to serving soldiers in varied terrains,” the defence ministry said in a statement.

The MoU was signed by Director General, Armed Forces Medical Services, Lt Gen Daljit Singh and Director, IIT-Delhi, Prof. Rangan Banerjee.

IIT-Delhi has a robust biomedical research ecosystem which is ideal for providing the technical expertise required for research in the diverse medical challenges faced in the armed forces, including rehabilitation of amputees, officials said.

Under the ambit of this agreement, faculty exchange programmes, joint academic activities and development of joint PhD programmes will also be planned, they said.On this occasion, Lt Gen Singh said AFMS is dedicated to providing the highest level of medical care to soldiers and collaboration with institutes of national importance like IITs is a significant step towards this commitment.

Related Posts

Indian Pharma Majors Plan to Invest in US

National Harbor (US): Top Indian pharmaceutical companies, including at least three from Hyderabad, are all set to announce major investments to set up new facilities in the United States during…

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at ₹243.74 crore in the fourth quarter ended March 2026 on the back of robust…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification